U.S. markets closed

MyMD Pharmaceuticals, Inc. (MYMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.99+0.47 (+5.52%)
At close: 4:00PM EDT
8.95 -0.04 (-0.44%)
After hours: 05:20PM EDT

MyMD Pharmaceuticals, Inc.

855 North Wolfe Street
Suite 623
Baltimore, MD 21205
United States
856 848 8698

Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Joshua N. SilvermanExec. ChairmanN/AN/A1970
Mr. Christopher C. SchreiberPres, CEO & DirectorN/AN/A1965
Dr. Christopher C. Chapman Jr.Pres & Chief Medical OfficerN/AN/A1953
Mr. Paul Rivard Esq.VP of Operations & Gen. CounselN/AN/AN/A
Dr. Adam Kaplin M.D., Ph.D.Chief Scientific OfficerN/AN/A1967
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.

Corporate Governance

MyMD Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.